Pentraxin 3 as a novel diagnostic marker in neonatal sepsis

Neonatal sepsis is an important cause of morbidity and mortality especially in developing countries. As clinical manifestations of neonatal sepsis are nonspecific, early diagnosis and treatment remain a challenge. Pentraxin 3 (PTX3) is an acute-phase protein secreted by various cells in response to the proinflammatory signals. Our aim was to investigate the diagnostic value of PTX3 in neonatal sepsis.
METHODS: We studied 90 neonates; 60 with culture-proven sepsis and 30 healthy neonates as a control group. Serum levels of PTX 3 were measured by ELISA.
RESULTS: Neonates with sepsis had significantly higher levels of PTX 3 as compared to controls (p < 0.001). Diagnostic cutoff value of PTX 3 was 5.6 μg/L with a sensitivity of 98.3% and a specificity of 96.7%. PTX 3 was significantly increased in nonsurvivors when compared to survivors (p < 0.001). PTX3 had better sensitivity when compared with CRP.
CONCLUSION: PTX 3 could be used as a new biomarker of neonatal sepsis with high sensitivity and specificity.

*Corresponding Author: 

Sameh Samir Fahmey, MD, Beni-Suef University, Beni Suef, Egypt, 6th Building, Road 272, New Maadi, Cairo, Egypt. +20 1001609715; E-mail: